TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32491941

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Learning (CAL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simulation Clinic (SIM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study: 34735285

Group type: EXPERIMENTAL
Intervention: Research staff obtained ESAS
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Clinically collected ESAS by nurses
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Proxy-reported ESAS
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Clinically collected ESAS by proxies
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: Follow-up ESAS measures
Number of subjects: 3533
Study: 36505223

Group type: EXPERIMENTAL
Intervention: USG-guided femoral nerve block (FNB) and lateral femoral cutaneous nerve block (LFCNB) using 0.75% ropivacaine before SAB
Number of subjects: 60

Group type: COMPARATOR
Intervention: SAB only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: USG-guided FNB and LFCNB
Number of subjects: 60
Study: 35792831

Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid with chondroitin sulphate (HA+CS)
Number of subjects: 10
Study: 32827307

Group type: EXPERIMENTAL
Intervention: Prophylactic nimodipine treatment (parenteral nimodipine from the day before surgery until the seventh postoperative day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prophylactic nimodipine treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 40
Study: 35063028

Group type: EXPERIMENTAL
Intervention: Intrabronchial administration of autologous adipose-derived mesenchymal stem cells (AD-MSC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral dexamethasone
Number of subjects: 20
Study: 34789149

Group type: EXPERIMENTAL
Intervention: Dementia Care Toolbox (used for 3 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting-list control (toolbox after follow-up)
Number of subjects: 32
Study: 32165444

Group type: EXPERIMENTAL
Intervention: SFA diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: SUGAR diet
Number of subjects: 16
Study: 616600062

Group type: EXPERIMENTAL
Intervention: Vocal cell phone conversation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Texting conversation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 35485693

Group type: EXPERIMENTAL
Intervention: Modified premedication protocol without ranitidine
Number of subjects: 441

Group type: COMPARATOR
Intervention: Standard premedication protocol with ranitidine
Number of subjects: 441
Study: 32036375

Group type: EXPERIMENTAL
Intervention: TAU + HEB
Number of subjects: 207

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 207
Study: 33583208

Group type: EXPERIMENTAL
Intervention: Nurse-conducted telephone guidance for bowel preparation before colonoscopy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (routine recommendations without telephone guidance)
Number of subjects: 109
Study: 32469375

Group type: EXPERIMENTAL
Intervention: Mind Mapping (MM) group, instructed on how to construct mind maps and created weekly mind maps for 9 weeks.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard Note-Taking Group (SNTG), followed their method of study without mind maps for 9 weeks.
Number of subjects: 74
Study: 33495909

Group type: EXPERIMENTAL
Intervention: Holistic Focus (HF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: External Focus (EF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Internal Focus (IF)
Number of subjects: 60
Study: 32852619

Group type: EXPERIMENTAL
Intervention: Oxygen-enriched oil-based gel dressing (G1)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Hyaluronic acid cream (G2)
Number of subjects: 114
Study: 35587950

Group type: EXPERIMENTAL
Intervention: Active coping (above-average)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Community connectedness at baseline
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Within-person change in active coping
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Within-person change in community connectedness
Number of subjects: 194
Study: 33618811

Group type: EXPERIMENTAL
Intervention: Video discharge instructions (verbal, written, and video discharge information)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Control group (verbal and written discharge information only)
Number of subjects: 771
Study: 32326983

Group type: EXPERIMENTAL
Intervention: Social skills training program led by childcare educators (n=185 children)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Wait list control (n=176 children)
Number of subjects: 361
Study: 36228127

Group type: EXPERIMENTAL
Intervention: AI-assisted diagnosis
Number of subjects: 104

Group type: COMPARATOR
Intervention: Independent diagnosis
Number of subjects: 104
Study: 33544534

Group type: EXPERIMENTAL
Intervention: Traditional resistance training (RT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Instability training (IT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Plyometric training (PLY)
Number of subjects: 65
Study: 33838918

Group type: EXPERIMENTAL
Intervention: Digital dentures (2 visits)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional dentures (5 visits)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Digital dentures
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 16
Study: 34476247

Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention (physical activity promotion through personalised, progressive step-count goals, feedback, online COPD-related education and social support via an online community)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 35545881

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32155289

Group type: EXPERIMENTAL
Intervention: PREOP risk score higher than 8
Number of subjects: 229

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 229
Study: 32169297

Group type: EXPERIMENTAL
Intervention: 17 RCTs
Number of subjects: 303
Study: 34369853

Group type: EXPERIMENTAL
Intervention: Uterine massage
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study: 32300910

Group type: EXPERIMENTAL
Intervention: Functional communication training (FCT) via telehealth
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 38
Study: 35840308

Group type: EXPERIMENTAL
Intervention: Removal of the collar (intervention)
Number of subjects: 887

Group type: COMPARATOR
Intervention: Hard collar (standard care)
Number of subjects: 887
Study: 33840404

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), n=33
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX), n=35
Number of subjects: 68
Study: 35978286

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 3345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3345

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg and 140 mg
Number of subjects: 3345
Study: 33880769

Group type: EXPERIMENTAL
Intervention: Expanded principal stratification framework allowing for partial adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo posterior sampling method
Number of subjects: 0
Study: 33323545

Group type: EXPERIMENTAL
Intervention: Leukocyte telomere length (LTL) as instrument variables using 5 independent SNPs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MR‐Egger intercept test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochran's Q test and I2 statistics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leave‐one‐out sensitivity analysis
Number of subjects: 0
Study: 33454539

Group type: EXPERIMENTAL
Intervention: Tablet-computer with survivor stories (3 times in 12 months)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 228
Study: 32384175

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35150025

Group type: EXPERIMENTAL
Intervention: Baseline assessment of physical function limitations using the Activities Scale for Kids©
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline assessment of exercise-related ADLs simulated with the Functional ADL Screen
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline assessment of motor performance using the Motor Performance in Paediatric Oncology test
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline assessment of physical activity level measured using an accelerometer
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cumulative steroid dose
Number of subjects: 41
Study: 33620545

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (140 mL, 13 mmol NO3‐)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NO3‐‐free placebo (PLA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation
Number of subjects: 10
Study: 32892178

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 35665223

Group type: EXPERIMENTAL
Intervention: Tangeretin (200 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33538566

Group type: EXPERIMENTAL
Intervention: Novel topical cosmetic cream (NCC), applied twice daily.
Number of subjects: 0
Study: 36463547

Group type: EXPERIMENTAL
Intervention: pertuzumab, trastuzumab, and docetaxel
Number of subjects: 243

Group type: COMPARATOR
Intervention: placebo, trastuzumab, and docetaxel
Number of subjects: 243
Study: 34446544

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 60
Study: 32119035

Group type: EXPERIMENTAL
Intervention: CBD10 (10 mg/kg/d)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: CBD20 (20 mg/kg/d)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 35672606

Group type: EXPERIMENTAL
Intervention: Omega-3/6 dietary supplement (two capsules containing 279 mg EPA, 87 mg DHA, 30 mg GLA each)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omega-3/6 dietary supplement
Number of subjects: 160
Study: 32162813

Group type: EXPERIMENTAL
Intervention: IV NEPA (fosnetupitant/palonosetron)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Oral NEPA
Number of subjects: 402
Study: 35878448

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention delivered by Anganwadi workers in 25 intervention clusters, with caregivers attending an average of five out of nine scheduled sessions.
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 530
Study: 33103938

Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention (PCI)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 479
Study: 35325589

Group type: EXPERIMENTAL
Intervention: Recruitment strategies across four randomized experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention strategies across four randomized experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Student feedback on participation improvement strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mandatory intervention completion at one university
Number of subjects: 0
Study: 32176674

Group type: EXPERIMENTAL
Intervention: Non-immersive VR training using a RAPAEL smart glove for 30 minutes per session, 3 days a week for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Recreational activities for 30 minutes per session, 3 days a week for 8 weeks (control group)
Number of subjects: 36
Study: 33257933

Group type: EXPERIMENTAL
Intervention: Non-sustained ventricular tachycardia (NSVT)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: High burden PVC
Number of subjects: 850

Group type: COMPARATOR
Intervention: Neither NSVT nor high burden of PVC
Number of subjects: 850
Study: 33061328

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting risk of injurious falls
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Independent risk factors identified
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 345
Study: 35941301

Group type: EXPERIMENTAL
Intervention: Single step dilatation (group B)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Serial metal track dilatation (group A)
Number of subjects: 70
Study: 34352149

Group type: EXPERIMENTAL
Intervention: Test formulation of Tenofovir Alafenamide (TAF)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Reference formulation of Tenofovir Alafenamide (TAF)
Number of subjects: 68
Study: 32559257

Group type: EXPERIMENTAL
Intervention: Higher admission systolic blood pressure (SBP)
Number of subjects: 21364

Group type: EXPERIMENTAL
Intervention: Lower admission systolic blood pressure (SBP)
Number of subjects: 21364
Study: 35230615

Group type: EXPERIMENTAL
Intervention: Whole-Day Good Behavior Game (WD)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Control
Number of subjects: 961
Study: 33625515

Group type: EXPERIMENTAL
Intervention: CR + VR
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual CR care
Number of subjects: 61
Study: 35701331

Group type: EXPERIMENTAL
Intervention: Remote-based monitoring and education program (three educational sessions by telephone)
Number of subjects: 134
Study: 35797913

Group type: EXPERIMENTAL
Intervention: Active iTBS treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham iTBS treatment
Number of subjects: 42
Study: 33377972

Group type: EXPERIMENTAL
Intervention: Capivasertib, 480 mg orally twice daily for 4 days on and 3 days off weekly in 28-day cycles; 400 mg if continuing hormone therapy for metastatic breast cancer.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Capivasertib
Number of subjects: 35
Study: 32065880

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI; ≥92.5%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34588374

Group type: EXPERIMENTAL
Intervention: Royal jelly 690 mg daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 32707226

Group type: EXPERIMENTAL
Intervention: Peanut (food challenge)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intravenous fluids (administered post-reaction)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Repeat peanut challenge
Number of subjects: 57
Study: 35986418

Group type: EXPERIMENTAL
Intervention: Injectable buprenorphine (BUP-XR)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Injectable buprenorphine (BUP-XR) with adjunctive psychosocial interventions (PSI)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Sublingual tablet buprenorphine (BUP-SL)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Oral liquid methadone (MET)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Sublingual tablet buprenorphine (BUP-SL) with PSI
Number of subjects: 304

Group type: COMPARATOR
Intervention: Oral liquid methadone (MET) with PSI
Number of subjects: 304
Study: 32253962

Group type: EXPERIMENTAL
Intervention: Intensive computer-based phonics (GraphoGame, GG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Regular schooling (RS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intensive computer-based phonics (GraphoGame, GG) after one period
Number of subjects: 17
Study: 32502505

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (PORT) for grade II IEPN
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (PORT) for grade III IEPN
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Adjuvant postoperative radiotherapy (PORT) for all grade II-III IEPNs
Number of subjects: 172
Study: 35964896

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 19373

Group type: COMPARATOR
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 19373

Group type: EXPERIMENTAL
Intervention: Risk-adapted screening
Number of subjects: 19373
Study: 33496536

Group type: EXPERIMENTAL
Intervention: Intraoperative freehand bilateral ESPB with a 20-mL mixture solution of 0.25% bupivacaine and 1.0% lidocaine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Physiological saline injection (Control)
Number of subjects: 56
Study: 32687091

Group type: EXPERIMENTAL
Intervention: Intralipid (IL) 20% infusion at 2 ml/kg, 30 min prior to revascularization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received normal saline infusion
Number of subjects: 30
Study: 83151875

Group type: EXPERIMENTAL
Intervention: Hepatic-Aid diet (20-g Casein/30-g Hepatic-Aid per day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Casein diet (50-g Casein per day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Hepatic-Aid diet
Number of subjects: 4
Study: 34118248

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU/d)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 33548749

Group type: EXPERIMENTAL
Intervention: Deep tissue massage (DTM) applied by midwife, twice at the 10th and 22nd hour after cesarean.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no applications performed).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep tissue massage (DTM) applied by midwife.
Number of subjects: 0
Study: 34959975

Group type: EXPERIMENTAL
Intervention: 4.0 mg Folic Acid
Number of subjects: 1060

Group type: COMPARATOR
Intervention: 0.4 mg Folic Acid
Number of subjects: 1060
Study: 35213275

Group type: EXPERIMENTAL
Intervention: Bayes factor method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utilizing historical data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posterior variance criterion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayes factor criterion
Number of subjects: 0
Study: 32601955

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic capsules (Bacillus coagulans Unique IS2, Lactobacillus rhamnosus UBLR58, Bifidobacterium lactis UBBLa70, Lactobacillus plantarum UBLP40 each of 2 billion CFU; Bifidobacterium breve UBBr01, Bifidobacterium infantis UBBI01 each of 1 billion CFU) with glutamine (250 mg) taken twice a day for 28 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo capsules taken twice a day for 28 days
Number of subjects: 80
Study: 34348666

Group type: EXPERIMENTAL
Intervention: LTV-h.PEEP ventilation (TV of 6 ml/IBW and PEEP of 10 cm H2O)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HTV-l.PEEP ventilation (TV of 10 ml/IBW and PEEP of 4 cm H2O)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined cohort
Number of subjects: 24
Study: 32364805

Group type: EXPERIMENTAL
Intervention: ER/DS mask (n=15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham mask (n=16)
Number of subjects: 31
Study: 32350847

Group type: EXPERIMENTAL
Intervention: Nanocurcumin (180 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 26
Study: 34957008

Group type: EXPERIMENTAL
Intervention: Camrelizumab combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 35409827

Group type: EXPERIMENTAL
Intervention: WeActive (aerobic and resistance training)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: WeMindful (mindful exercise)
Number of subjects: 55
Study: 33958436

Group type: EXPERIMENTAL
Intervention: FACE‐TC (Advance Care Planning Survey; Next Steps: Respecting Choices; Five Wishes)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 126
Study: 33261710

Group type: EXPERIMENTAL
Intervention: Livestock-transfer programs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Leveraging livestock products for nutrition
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Helping farmers manage priority diseases
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Disease control interventions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Interventions related to livestock production
Number of subjects: 78
Study: 34641706

Group type: EXPERIMENTAL
Intervention: PZL (50 μg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LT3 (50 μg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 12
Study: 33864342

Group type: EXPERIMENTAL
Intervention: Prophylactic mesh placement at the primary operation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Differing surgical techniques
Number of subjects: 0
Study: 34076067

Group type: EXPERIMENTAL
Intervention: 150 mg of CBD powder
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 150 mg of CBD dissolved in corn oil
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 32795623

Group type: EXPERIMENTAL
Intervention: Flexibility intervention group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strength intervention group
Number of subjects: 20
Study: 32740218

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with or without vitamin K2 or vitamin K antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular-dose apixaban (5 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-dose apixaban (2.5 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apixaban initiation
Number of subjects: 0
Study: 34559269

Group type: EXPERIMENTAL
Intervention: TAA-soaked nasal packing
Number of subjects: 104

Group type: COMPARATOR
Intervention: Saline-impregnated dressing
Number of subjects: 104
Study: 32781931

Group type: EXPERIMENTAL
Intervention: Males (n=122)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Females (n=183)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: General anxiety and number of cancer symptoms (both genders)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 305